Work

Nivolumab (Nivo) + platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: Results from CheckMate 227.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.9001

Authors: Hossein Borghaei, Matthew David Hellmann, Luis G. Paz-Ares, Suresh S. Ramalingam, Martin Reck, Kenneth John O'Byrne, Prabhu Bhagavatheeswaran, Faith Ellen Nathan, Julie R. Brahmer

Institutions: Fox Chase Cancer Center, Memorial Sloan Kettering Cancer Center, Hospital Universitario 12 De Octubre, Emory University, Winship Cancer Institute, German Center for Lung Research, LungenClinic Grosshansdorf, Princess Alexandra Hospital, Bristol-Myers Squibb (United States), Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2892009523

Cites:

Cited by: 87

Related to: 10